Company name



Academic Medical Center Amsterdam

The company

Based on its proprietary findings, Regenesance currently has three programs for drug development, which target the complement pathway in order to treat immune mediated disorders and to accelerate nerve regeneration in neurological disorders.

Regenesance has developed monoclonal antibody Regenemabâ„¢ for the treatment of neurodegenerative and immune mediated disorders, first target indication is PNH. The Company was founded in 2009 based on findings that inhibiting complement system factor C6 is safe and effective to block the formation of the Membrane Attack Complex and therefore preventing unwanted lysis. Since unwanted lysis by complement activation is involved in many indications, the Regenesance antibody is suitable for multiple indications like PNH, Myasthenia Gravis, Amyotrophic Lateral Sclerosis and Multiples Sclerosis.